KRAS and endometrioid tumor: According to the TCGA report, most endometrioid tumors expressed frequent mutations in PTEN, CTNNB1, PIK3CA, ARID1A, and KRAS. By contrast, serous tumors and high-grade endometrioid tumors had frequent P53 mutations.